Dr. Franco Lori, CEO ViroStatics “AV-HALTs: AntiViral–HyperActivation Limiting Therapeutics” Video Biotech 2012 SF

http://virostatics.com/index.html

Virostatics is a biotech company working to help the immune system to combat chronic diseases. SNNLive spoke with Dr. Franco Lori, CEO of ViroStatics at the BioTech Showcase 2012 in San Francisco, CA. Dr. Lori Founded ViroStatics in 2005, serving as President and Chief Executive Officer. He has over twenty years of extensive experience in Biotech management, and has overseen the successful start-up of three biotechnology companies.

The problem is that the immune system is activated in response to a virus such as HIV and is then unable to cool down again, which becomes a disease itself–the patient ages ten or fifteen years due to bone loss, stroke, heart attacks, and liver and kidney diseases that are the consequence of this hyperactivation of the immune system. Most treatments only treat viruses and don’t address this hyperactivation of the immune system.

Dr. Lori says, “We want to do both; we want to decrease viral load, and we want to protect the immune system from the consequences of the virus.” Focusing on HIV, Virostatics is developing a new generation of drugs designed to change the course of the disease. For more information about ViroStatics, check out their website. SNNLive welcomes Dr. Franco Lori, CEO of ViroStatics.